PerezE.A.: Current management of metastatic breast cancer.Semin Oncol, 26(Suppl 12): 1–10, 1999.
2.
NortonL.: Salvage chemotherapy of breast cancer.Semin Oncol, 21: 19–24, 1994.
3.
PiccartM.: Treatment of advanced breast cancer: current status.Antic Drugs, 7(Suppl 2): 5–7, 1996.
4.
CarmichaelJ.: The role of gemcitabine in the treatment of other tumours.Br J Cancer, 78(Suppl 3): 21–25, 1998.
5.
CarmichaelJ., PossingerK., PhillipP.: Advanced breast cancer: a phase II trial with gemcitabine.J Clin Oncol, 13: 2731–2736, 1995.
6.
SpielmannM., Llombart-CussacA., KallaS.: Single-agent gemcitabine is active in previously treated metastatic breast cancer.Oncology, 60: 303–307, 2001.
7.
SilvestrisN., D'AprileM., AndreolaG.: Rationale for the use of gemcitabine in breast cancer.Int J Oncol, 24: 389–398, 2004.
8.
O'ShaughnessyJ., TwelvesC., AaproM.: Treatment for anthracycline-pretreated metastatic breast cancer.Oncologist:7(Suppl 6): 4–12, 2002.
9.
AlbainK.S., NagS., Calderillo-RuizG.: Global phase III study of gemcitabine plus paclitaxel versus paclitaxel as frontline therapy for metastatic breast cancer.Proc ASCO2004, abs 510.
10.
O'ShaughnessyJ., NagS., Calderillo-RuizG.: Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study.Proc ASCO2003, abs 25.
11.
MoinpourC., WuJ., DonaldsonA.: Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): quality of life and pain palliation results from the global phase III study.Proc ASCO2004, abs 621.
